Logo image of APRI

Apricus Biosciences Inc (APRI) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:APRI -

0.22
-0.01 (-4.35%)
Last: 1/23/2019, 8:00:00 PM
0.24
+0.02 (+9.09%)
After Hours: 1/23/2019, 8:00:00 PM

APRI Key Statistics, Chart & Performance

Key Statistics
Market Cap6.20M
Revenue(TTM)N/A
Net Income(TTM)-9.83M
Shares28.17M
Float27.60M
52 Week High3.34
52 Week Low0.18
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-0.52
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


APRI short term performance overview.The bars show the price performance of APRI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30 -40

APRI long term performance overview.The bars show the price performance of APRI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APRI is 0.22 null. In the past month the price increased by 15.79%. In the past year, price decreased by -90.52%.

Apricus Biosciences Inc / APRI Daily stock chart

APRI Latest News, Press Relases and Analysis

About APRI

Company Profile

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.

Company Info

Apricus Biosciences Inc

11975 EL CAMINO REAL SUITE 300

SAN DIEGO CA 92130

CEO: Richard W. Pascoe

Phone: 858-222-8041

Apricus Biosciences Inc / APRI FAQ

What does Apricus Biosciences Inc do?

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.


What is the stock price of Apricus Biosciences Inc today?

The current stock price of APRI is 0.22 null. The price decreased by -4.35% in the last trading session.


Does APRI stock pay dividends?

APRI does not pay a dividend.


How is the ChartMill rating for Apricus Biosciences Inc?

APRI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy APRI stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APRI.


APRI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to APRI. When comparing the yearly performance of all stocks, APRI is a bad performer in the overall market: 98.39% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

APRI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to APRI. Both the profitability and financial health of APRI have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APRI Financial Highlights

Over the last trailing twelve months APRI reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 13.16% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -176.71%
ROE -239.05%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%N/A
EPS 1Y (TTM)13.16%
Revenue 1Y (TTM)N/A

APRI Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y59.6%
Revenue Next YearN/A

APRI Ownership

Ownership
Inst Owners19.89%
Ins Owners18.31%
Short Float %N/A
Short RatioN/A